Document:

Exhibit 10.1

 

 

*** OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION

CONFIDENTIAL TREATMENT REQUESTED UNDER
17 C.F.R. SECTION 240.24b-2

 

AMENDMENT N°4 TO

PRODUCT RESEARCH, DEVELOPMENT, 

LICENSE AND COMMERCIALIZATION AGREEMENT

 

This amendment to the Agreement (hereinafter
referred to as the "Amendment") is entered into on November 5, 2013 by and between:

 

INTERCEPT PHARMACEUTICALS, INC.

a corporation organized and existing under
the laws of Delaware, with registered office at 18 Desbrosses Street, New York, NY 10013, USA

 

(hereinafter referred to as “INTERCEPT”)

On the one hand

 

AND

 

 

LES LABORATOIRES SERVIER

a corporation organized and existing under
the laws of France, with registered office at 50 rue Carnot 92284 Suresnes cedex, France

 

and

 

INSTITUT DE RECHERCHES SERVIER

a corporation organized and existing under
the laws of France, with registered office at 3 rue de la République, 92150 Suresnes, France

 

(these two entities are jointly referred
to as “SERVIER”)

On the other hand.

 

 

RECITALS

 

WHEREAS, INTERCEPT
and SERVIER have executed on August 1st, 2011 a product research, development, license and commercialization agreement
(hereinafter the “Original Agreement”);

 

WHEREAS, the
initial Research Program Term (as defined in section 2.1 of the Agreement) ended on July 31st, 2012;

 

WHEREAS, the
Parties have extended such Research Program Term until September 30th, 2013 by way of three amendments (the “First
Amendment” dated 24th July 2012, the "Second Amendment" dated 15 February 2013 the “Third
Amendment” dated August 1st, 2013 and the Original Agreement, as amended by the First, Second and Third Amendments,
the “Agreement”);

 

WHEREAS, the
Parties have decided to further extend such Research Program Term for an additional two year period commencing on October 1st,
2013;

 

NOW, THEREFORE,
in consideration of the foregoing premises, SERVIER and INTERCEPT hereby agree as follows:

 

    	1

    	 

    

 

Article
1: 

  

Unless otherwise indicated below, this
Amendment shall be of effect starting on October 1st, 2013, and the Research Program Term is extended for
a two years period starting on October 1st, 2013 (hereinafter the “Extended Term”).

 

During
the Extended Term, INTERCEPT shall conduct the research activities described in Schedule 1 to this Amendment. In terms of manpower,
it is intended that INTERCEPT will allocate for the performance of the research activities up to [***] full
time equivalent personnel which shall include the work as outlined in the Research Program as amended pursuant to Schedule 1 to
this Amendment. SERVIER will reimburse to INTERCEPT at the end of each three month period of service during the Extended Term an
amount of EUR [***] per FTE, up to a maximum of EUR [***]
for each three month period, provided such costs are duly justified.

 

INTERCEPT will provide an intermediate
report every 6 months and a final report within 30 days after the end of the Extended Term.

 

Article
2:

 

Schedule 1 of the Agreement
shall, as of the date of this Amendment, be supplemented with Schedule 1 attached to this Amendment.

 

Article
3:

 

This Amendment shall be governed by and
construed under the laws of Switzerland, without giving effect to the conflict of law principles thereof.

 

Any and all provisions of the Agreement
not modified hereinabove shall remain in full force and effect.

 

[Remainder of Page Intentionally Left
Blank; Signature Page Follows]

 

    	2

    	 

    

In witness whereof, the Parties have executed
this Amendment by their proper officers as of the date first set forth above.

 

	INTERCEPT PHARMACEUTICALS, INC.	LES LABORATOIRES SERVIER
	 	 
	 	 
	/s/ Mark Pruzanski	/s/ Marie-Christine Larcher
	 	 
	Mark PRUZANSKI	Mrs Marie-Christine LARCHER
	 	 
	President and CEO	Proxy
	 	 
	 	 
	 	INSTITUT DE RECHERCHES SERVIER
	 	 
	 	 
	 	/s/ Emmanuel Canet
	 	 
	 	Dr Emmanuel CANET
	 	 
	 	President R&D

 

 

    	3

    	 

    

SCHEDULE 1

 

 

[***]

Schedule 1 pg. 1 of 16

 

 

 

 

    	 

    	 

    

 

[***]

Schedule 1 pg. 2 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Schedule 1 pg. 3 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Schedule 1 pg. 4 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Schedule 1 pg. 5 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Schedule 1 pg. 6 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Schedule 1 pg. 7 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Schedule 1 pg. 8 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Schedule 1 pg. 9 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Schedule 1 pg. 10 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Schedule 1 pg. 11 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Schedule 1 pg. 12 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Schedule 1 pg. 13 of 16

 

 

 

 

 

 

    	 

    	 

    

 

[***]

Schedule 1 pg. 14 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Schedule 1 pg. 15 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Schedule 1 pg. 16 of 16Exhibit 10.2

 

*** OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION

CONFIDENTIAL TREATMENT REQUESTED UNDER
17 C.F.R. SECTION 240.24b-2

 

AMENDMENT NO. 4 TO

CONSULTING AND INTELLECTUAL PROPERTY
(“IP”) AGREEMENT

 

This
Amendment No. 4 to Consulting and Intellectual Property (“IP”) Agreement (this “Amendment”), dated November
5, 2013, is entered into by and between INTERCEPT PHARMACEUTICALS, INC., a
corporation organized and existing under the laws of Delaware, with its registered office at 18 Desbrosses Street, New York, NY
10013, USA (“INTERCEPT”), on the one hand and ROBERTO PELLICCIARI
(“Consultant”), residing at Via U. Rocchi, 60, Perugia, Italy 06123, on the other hand:

 

RECITALS

 

WHEREAS, INTERCEPT and Consultant
have entered into a Consulting and Intellectual Property Agreement, dated August 1, 2011 (the “Original Agreement”),
as amended by Amendment No. 1 to Consulting and Intellectual Property Agreement, dated as of July 30, 2012 (the “First Amendment”),
Amendment No. 2 to Consulting and Intellectual Property Agreement, dated as of February 15, 2013 (the “Second Amendment”),
and Amendment No. 3 to Consulting and Intellectual Property Agreement, dated as of August 1, 2013 (the “Third Amendment”
and the Original Agreement as amended by the First Amendment, the Second Amendment and the Third Amendment, the “Agreement”);

 

WHEREAS, the Term (as defined in
the Original Agreement), as extended, was further extended until September 30, 2013 pursuant to the Third Amendment; and

 

WHEREAS, the parties have decided
to further extend such Term.

 

NOW, THEREFORE,
in consideration of the foregoing premises, INTERCEPT and Consultant hereby agree as follows:

 

ARTICLE
1: 

 

This Amendment shall be of effect starting
on October 1, 2013, and the Term under the Agreement shall be extended for a two year period starting on October 1, 2013 (hereinafter
the “Extended Term”).

 

During
the Extended Term, Consultant agrees to make himself available to render the Services, as requested by INTERCEPT at such
times and locations as may be mutually agreed and to perform such Services in a professional and workmanlike manner. INTERCEPT
will pay to Consultant thirty-seven thousand five hundred euros (€37,500) for each three-month period of service during the
Extended Term for consulting services and Inventions, Know How, Improvements and Patent Rights to be provided by Consultant. Payment
shall be made on the last day of each three-month period of service during the Extended Term (or, if such day is not a business
day in the United States, the immediately following business day).

 

ARTICLE
2: 

 

Exhibit A of the Agreement shall be deleted
and replaced in its entirety with Exhibit A attached to this Amendment.

 

 

    	page 1 of 3

    	 

    

 

ARTICLE
3:

 

This Amendment shall be governed by and
construed under the laws of the State of New York, U.S., without giving effect to the conflict of law principles thereof.

 

Any and all provisions of the Agreement
not modified hereinabove shall remain in full force and effect.

 

[Remainder of Page Intentionally Left
Blank; Signature Page Follows]

 

 

 

    	page 2 of 3

    	 

    

 

In
witness whereof, the Parties have executed this Amendment by their proper officers as of the date first set forth above.

 

 

 

	 	INTERCEPT PHARMACEUTICALS,
    INC.
	 	 
	 	 
	 	/s/ Mark Pruzanski	 
	 	Name: Mark Pruzanski
	 	Title: President and Chief Executive Officer
	 	 
	 	 
	 	CONSULTANT
	 	 
	 	 
	 	/s/ Roberto
    Pellicciari	 
	 	Name: Roberto Pellicciari

 

 

 

 

 

 

 

[Signature Page – Pellicciari Consulting
Agreement (TGR5) – Amendment No. 4]

    	page 3 of 3

    	 

    

 

Exhibit A

 

Action Plan

 

 

[***]

Exhibit A pg. 1 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Exhibit A pg. 2 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Exhibit A pg. 3 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Exhibit A pg. 4 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Exhibit A pg. 5 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Exhibit A pg. 6 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Exhibit A pg. 7 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Exhibit A pg. 8 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Exhibit A pg. 9 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Exhibit A pg. 10 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Exhibit A pg. 11 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Exhibit A pg. 12 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Exhibit A pg. 13 of 16

 

 

 

 

    	 

    	 

    

 

[***]

Exhibit A pg. 14 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Exhibit A pg. 15 of 16

 

 

 

 

 

    	 

    	 

    

 

[***]

Exhibit A pg. 16 of 16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]